Contrive Datum Insights has published "Cell Cryopreservation Consumables Market Size, Share & Industry Analysis, By Product type (Cryopreservation Media, Cryovials / Cryogenic Vials, Cryobags / Freezing Bags, Cryogenic Tubes & Straws, Cryoboxes, Racks & Storage Systems, Labels & Identification Systems, Caps, Closures & Seals), Cryoprotectant type (DMSO-Based Formulations, DMSO-Free Formulations, Serum-Containing Formulations, Serum-Free / Xeno-Free Formulations, Custom & Proprietary Blends), Container material (Polypropylene, Glass, Ethylene Vinyl Acetate (EVA), Fluoropolymer (FEP/PFA), Cyclic Olefin Copolymer (COC)), Fill volume / capacity (Small-Volume (<2 mL), Mid-Volume (2-5 mL), High-Volume Bags (>5 mL to Multi-Liter)), Product grade (GMP / Clinical-Grade, Research-Use-Only (RUO) Grade), Application / cell type (Stem Cells, Immune Effector Cells (CAR-T/NK/TIL), Oocytes & Embryos, Sperm Cells, Hepatocytes & Primary Cells, Whole Blood & Blood Components, Tissues & Other Biospecimens), End user (Biopharmaceutical & Biotechnology Companies, Cell & Gene Therapy CDMOs/CMOs, Academic & Research Institutes, Biobanks & Cell/Tissue Banks, IVF & Fertility Clinics, Blood Banks & Transfusion Centers, Hospitals & Diagnostic Laboratories), Sales / distribution channel (Direct Sales, Distributors & Resellers, Online / E-Commerce Platforms), and Regional Forecast, 2026-2034". The study sizes the global cell cryopreservation consumables market at USD 5.15 billion in 2025 and projects growth from USD 5.72 billion in 2026 to USD 13.29 billion by 2034, a compound annual growth rate of 11.11% across the forecast period.
Cell cryopreservation consumables are the media, containers and ancillary products used to freeze, store and thaw living cells, tissues and other biospecimens without destroying their viability. The category spans cryoprotectant media formulated to protect cells during freezing, and the vials, bags, tubes, boxes, racks, labels and closures that hold and identify a sample through long-term cryogenic storage. Buyers include biopharmaceutical and cell therapy manufacturers, academic and clinical research laboratories, biobanks, fertility clinics and blood banks, each qualifying a specific combination of media and container for its own cell type and process.
Expansion of cell and gene therapy manufacturing capacity
Expansion of cell and gene therapy manufacturing capacity is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11.11% a year, the product type lines exposed to it move fastest: Cryobags / Freezing Bags compounds at 13.52%, taking its share of revenue from 14% to 17% and its value from USD 0.72 billion to USD 2.26 billion.
Where the forecast could be beaten: the bull case assumes cell and gene therapy manufacturers commit capital to commercial-scale manufacturing capacity faster than currently announced, pulling forward cryobag and GMP-grade media demand, and that serum-free formulation switching happens ahead of the base case's qualification-timeline assumption. The study puts that case at USD 14.73 billion in 2034, against USD 13.29 billion in the base.
Against that, the bear case assumes delayed reimbursement decisions and financing constraints slow announced cell and gene therapy manufacturing build-outs, holding cryovial-based clinical-scale demand closer to current volumes and pushing formulation-switching timelines out beyond the base case. On that reading 2034 revenue stops at USD 11.5 billion. The weight of the problem sits in Cryovials / Cryogenic Vials: 28% of 2025 revenue growing at 9.73%, well under the market's 11.11%.
Cryopreservation Media Scale Against Cryobags / Freezing Bags Momentum
The product type axis, not the regional one, is what divides the field. Cryopreservation Media is the volume position, 32% of 2025 revenue at USD 1.65 billion, holding 33% through 2034, and it is defended by scale. Cryobags / Freezing Bags is the growth position at 13.52%, and it is open. Strength in one does not carry into the other.
What Else the Report Shows
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Cryoprotectant type | DMSO-Based Formulations | 55% · USD 2.83 billion | Serum-Free / Xeno-Free Formulations 17.35% |
| Container material | Polypropylene | 58% · USD 2.99 billion | Cyclic Olefin Copolymer (COC) 17.56% |
| Fill volume / capacity | Small-Volume (<2 mL) | 45% · USD 2.32 billion | High-Volume Bags (>5 mL to Multi-Liter) 15.34% |
| Product grade | Research-Use-Only (RUO) Grade | 58% · USD 2.99 billion | GMP / Clinical-Grade 13.8% |
| Application / cell type | Stem Cells | 30% · USD 1.55 billion | Immune Effector Cells (CAR-T/NK/TIL) 14.15% |
| End user | Biopharmaceutical & Biotechnology Companies | 28% · USD 1.44 billion | Cell & Gene Therapy CDMOs/CMOs 14.41% |
| Sales / distribution channel | Direct Sales | 55% · USD 2.83 billion | Online / E-Commerce Platforms 19.05% |
- Regionally, the lead sits with North America: 43% of 2025 global revenue, USD 2.21 billion rising to USD 5.32 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 24% in 2025 to 28% in 2034, with revenue growing from USD 1.24 billion to USD 3.72 billion.
- Middle East and Africa stays the smallest contributor across the period: 3% of revenue in 2025 and 3.5% in 2034.
- Cryopreservation Media was the leading product type line in 2025, taking 32% of revenue at USD 1.65 billion.
- No product type line grows faster than Cryobags / Freezing Bags, at a projected 13.52%.
- The United States is the largest single country market at USD 1.72 billion in 2025, 33.4% of global revenue.
The study covers eight axes, by product type, and by cryoprotectant type, container material, fill volume / capacity, product grade, application / cell type, end user and sales / distribution channel, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with bear, base and bull scenarios on the headline total at USD 11.5 billion and USD 14.73 billion by 2034. Country-level detail is given for all five regions, together with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.